Overlap Syndromes

Ulrich Beuers; Christian Rust

doi:10.1055/s-2005-916322

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2005; 25(3): 311-320
DOI: 10.1055/s-2005-916322

Overlap Syndromes

Ulrich Beuers¹ ^, ² , Christian Rust²

¹Professor of Medicine, Department of Medicine II - Grosshadern, Ludwig Maximilians-University of Munich, Munich, Germany
²Department of Medicine II - Grosshadern, Ludwig Maximilians-University of Munich, Munich, Germany

Abstract

ABSTRACT

In hepatology, the term overlap syndrome describes variant forms of the major hepatobiliary autoimmune diseases, autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Patients with overlap syndromes present with both hepatitic and cholestatic biochemical and histological features of AIH, PBC, and/or PSC, and usually show a progressive course toward liver cirrhosis and liver failure without adequate treatment. AIH-PBC overlap syndromes have been reported in almost 10% of adults with AIH or PBC, whereas AIH-PSC overlap syndromes were found in 6 to 8% of children, adolescents, and young adults with AIH or PSC. A minority of patients may also show transition from stable PBC to AIH, AIH to PBC, or AIH to PSC, as documented by single case reports and small case series. Single cases of AIH and autoimmune cholangitis (antimitochondrial antibody-negative PBC) overlap have also been reported. Empiric medical treatment of AIH-PBC and AIH-PSC overlap syndromes includes anticholestatic therapy with ursodeoxycholic acid and immunosuppressive therapy with corticosteroids and azathioprine. In end-stage disease, liver transplantation is the treatment of choice.

KEYWORDS

Autoimmune hepatitis - primary biliary cirrhosis - primary sclerosing cholangitis - cholestasis - hepatitis - autoimmune cholangitis

Volltext

Referenzen

REFERENCES

1 Czaja A J. The variant forms of autoimmune hepatitis. Ann Intern Med. 1996; 125 588-598
2 Heathcote E J. Overlap syndromes. In: Bircher J, Beuhamou JP, McIntyre N, Rizzetto M, Rodès J Oxford Textbook of Clinical Hepatology, Vol. 2. Oxford, United Kingdom; Oxford University Press 1999: 1135-1140
3 Woodward J, Neuberger J. Autoimmune overlap syndromes. Hepatology. 2001; 33 994-1002
4 Poupon R. Autoimmune overlapping syndromes. Clin Liver Dis. 2003; 7 865-878
5 Colombato L A, Alvarez F, Cote J, Huet P M. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis?. Gastroenterology. 1994; 107 1839-1843
6 Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998; 28 296-301
7 Gregorio G V, Portmann B, Karani J et al.. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001; 33 544-553
8 Abdo A A, Bain V G, Kichian K, Lee S S. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology. 2002; 36 1393-1399
9 Beuers U. Hepatic overlap syndromes. J Hepatol. 2005; 42(suppl 1) S93-S99
10 Alvarez F, Berg P A, Bianchi F B et al.. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999; 31 929-938
11 Kanzler S, Weidemann C, Gerken G et al.. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol. 1999; 31 635-640
12 Terjung B, Bogsch F, Klein R et al.. Diagnostic accuracy of atypical p-ANCA in autoimmune hepatitis using ROC- and multivariate regression analysis. Eur J Med Res. 2004; 9 439-448
13 Prince M I, Chetwynd A, Craig W L, Metcalf J V, James O F. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut. 2004; 53 865-870
14 Vierling J M. Primary biliary cirrhosis and autoimmune cholangiopathy. Clin Liver Dis. 2004; 8 177-194
15 Heathcote E J. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000; 31 1005-1013
16 Wiesner R H, LaRusso N F, Ludwig J, Dickson E R. Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology. 1985; 88 108-114
17 Ludwig J, Colina F, Poterucha J J. Granulomas in primary sclerosing cholangitis. Liver. 1995; 15 307-312
18 Lee Y M, Kaplan M M. Primary sclerosing cholangitis. N Engl J Med. 1995; 332 924-933
19 Heathcote J. Autoimmune cholangitis. Gut. 1997; 40 440-442
20 Brunner G, Klinge O. A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis) [in German]. Dtsch Med Wochenschr. 1987; 112 1454-1458
21 Ben-Ari Z, Dhillon A P, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology. 1993; 18 10-15
22 Sherlock S. Ludwig Symposium on biliary disorders. Autoimmune cholangitis: a unique entity?. Mayo Clin Proc. 1998; 73 184-190
23 Czaja A J, Carpenter H A, Santrach P J, Moore S B. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology. 2000; 31 1231-1238
24 Michieletti P, Wanless I R, Katz A et al.. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut. 1994; 35 260-265
25 Taylor S L, Dean P J, Riely C A. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Surg Pathol. 1994; 18 91-99
26 Goodman Z D, McNally P R, Davis D R, Ishak K G. Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases. Dig Dis Sci. 1995; 40 1232-1242
27 Omagari K, Ikuno N, Matsuo I et al.. Autoimmune cholangitis syndrome with a bias towards primary biliary cirrhosis. Pathology. 1996; 28 255-258
28 Invernizzi P, Crosignani A, Battezzati P M et al.. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology. 1997; 25 1090-1095
29 Kinoshita H, Omagari K, Whittingham S et al.. Autoimmune cholangitis and primary biliary cirrhosis-an autoimmune enigma. Liver. 1999; 19 122-128
30 Neuberger J, Thomson R. PBC and AMA-what is the connection?. Hepatology. 1999; 29 271-276
31 Miyakawa H, Tanaka A, Kikuchi K et al.. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology. 2001; 34 243-248
32 Tsuneyama K, Van De Water J, Van Thiel D et al.. Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody-negative primary biliary cirrhosis. Hepatology. 1995; 22 1440-1446
33 Ikuno N, Scealy M, Davies J M et al.. A comparative study of antibody expressions in primary biliary cirrhosis and autoimmune cholangitis using phage display. Hepatology. 2001; 34 478-486
34 Gordon S C, Quattrociocchi-Longe T M, Khan B A et al.. Antibodies to carbonic anhydrase in patients with immune cholangiopathies. Gastroenterology. 1995; 108 1802-1809
35 Ohana M, Okazaki K, Hajiro K, Uchida K. Antilactoferrin antibodies in autoimmune liver diseases. Am J Gastroenterol. 1998; 93 1334-1339
36 Comay D, Cauch-Dudek K, Hemphill D, Diamandis E, Wanless I, Heathcote E J. Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis?. Dig Dis Sci. 2000; 45 2018-2021
37 Muratori L, Muratori P, Zauli D et al.. Antilactoferrin antibodies in autoimmune liver disease. Clin Exp Immunol. 2001; 124 470-473
38 Lacerda M A, Ludwig J, Dickson E R, Jorgensen R A, Lindor K D. Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol. 1995; 90 247-249
39 Kim W R, Poterucha J J, Jorgensen R A et al.. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology. 1997; 26 22-26
40 James O F, Bhopal R, Howel D, Gray J, Burt A D, Metcalf J V. Primary biliary cirrhosis once rare, now common in the United Kingdom?. Hepatology. 1999; 30 390-394
41 Kim W R, Lindor K D, Locke III G R et al.. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology. 2000; 119 1631-1636
42 Boberg K M, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998; 33 99-103
43 Geubel A P, Baggenstoss A H, Summerskill W H. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome. Gastroenterology. 1976; 71 444-449
44 Kloppel G, Seifert G, Lindner H, Dammermann R, Sack H J, Berg P A. Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity. Virchows Arch A Pathol Anat Histol. 1977; 373 143-160
45 Gheorghe L, Iacob S, Gheorghe C et al.. Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease. Eur J Gastroenterol Hepatol. 2004; 16 585-592
46 Lohse A W, zum Buschenfelde K H, Franz B, Kanzler S, Gerken G, Dienes H P. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology. 1999; 29 1078-1084
47 Yamamoto K, Terada R, Okamoto R et al.. A scoring system for primary biliary cirrhosis and its application for variant forms of autoimmune liver disease. J Gastroenterol. 2003; 38 52-59
48 Terjung B, Spengler U. Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases. Clin Rev Allergy Immunol. 2005; 28 115-133
49 Kanzler S, Bozkurt S, Herkel J, Galle P R, Dienes H P, Lohse A W. Presence of SLA/LP autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmune hepatitis (overlap syndrome) [in German]. Dtsch Med Wochenschr. 2001; 126 450-456
50 Beuers U. Overlap syndromes. In: Gershwin ME, Vierling, JM, Manns, MP Liver Immunology Philadelphia, PA; Hanley & Belfus 2003: 363-371
51 Leuschner U. Autoimmunkrankheiten der Leber und Overlapsyndrome. Bremen, Germany; UNI-MED Verlag 2001
52 Duclos-Vallee J C, Hadengue A, Ganne-Carrie N, Robin E, Degott C, Erlinger S. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by cyclosporine A. Dig Dis Sci. 1995; 40 1069-1073
53 el-Shabrawi M, Wilkinson M L, Portmann B et al.. Primary sclerosing cholangitis in childhood. Gastroenterology. 1987; 92 1226-1235
54 Rabinovitz M, Demetris A J, Bou-Abboud C F, Van Thiel D H. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig Dis Sci. 1992; 37 1606-1611
55 Lawrence S P, Sherman K E, Lawson J M, Goodman Z D. A 39 year old man with chronic hepatitis. Semin Liver Dis. 1994; 14 97-105
56 Debray D, Pariente D, Urvoas E, Hadchouel M, Bernard O. Sclerosing cholangitis in children. J Pediatr. 1994; 124 49-56
57 Wilschanski M, Chait P, Wade J A et al.. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology. 1995; 22 1415-1422
58 Gohlke F, Lohse A W, Dienes H P et al.. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol. 1996; 24 699-705
59 McNair A N, Moloney M, Portmann B C, Williams R, McFarlane I G. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol. 1998; 93 777-784
60 van Buuren H R, van Hoogstraten H JE, Terkivatan T, Schalm S W, Vleggaar F P. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol. 2000; 33 543-548
61 Kaya M, Angulo P, Lindor K D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol. 2000; 33 537-542
62 Chazouilleres O. Diagnosis of primary sclerosing cholangitis-autoimmune hepatitis overlap syndrome: to score or not to score?. J Hepatol. 2000; 33 661-663
63 Beuers U, Spengler U, Kruis W et al.. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. 1992; 16 707-714
64 Stiehl A. Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis. Scand J Gastroenterol Suppl. 1994; 204 59-61
65 Lindor K D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med. 1997; 336 691-695
66 Mitchell S A, Bansi D S, Hunt N, Von Bergmann K, Fleming K A, Chapman R W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology. 2001; 121 900-907
67 Czaja A J, Carpenter H A. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology. 2001; 34 659-665
68 Li C P, Tong M J, Hwang S J et al.. Autoimmune cholangitis with features of autoimmune hepatitis: successful treatment with immunosuppressive agents and ursodeoxycholic acid. J Gastroenterol Hepatol. 2000; 15 95-98
69 Rubel L R, Seeff L B, Patel V. Primary biliary cirrhosis-primary sclerosing cholangitis overlap syndrome. Arch Pathol Lab Med. 1984; 108 360-361
70 Burak K W, Urbanski S J, Swain M G. A case of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases. Dig Dis Sci. 2001; 46 2043-2047
71 Zanger U M, Hauri H P, Loeper J, Homberg J C, Meyer U A. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA. 1988; 85 8256-8260
72 Manns M P, Johnson E F, Griffin K J, Tan E M, Sullivan K F. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest. 1989; 83 1066-1072
73 Manns M P, Griffin K J, Sullivan K F, Johnson E F. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest. 1991; 88 1370-1378
74 Manns M P, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology. 1997; 26 1054-1066
75 Lunel F, Abuaf N, Frangeul L et al.. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology. 1992; 16 630-636
76 Pawlotsky J M, Ben Yahia M, Andre C et al.. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology. 1994; 19 841-848
77 Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol. 1999; 31 210-216

Ulrich BeuersM.D.

Department of Medicine II-Grosshadern, Ludwig Maximilians-University of Munich

Marchioninistrasse 15, 81377 Munich, Germany

eMail: Beuers@med.uni-muenchen.de